EarningsQ2 2026 Earnings Report

10x Genomics (TXG) Q2 2026 Earnings Report

0 Followers

Previous Report: Q1 2026

MX:TXG Q2 2026 EPS Results

Actual EPS-$2.54

Consensus EPS-$4.41

Beat/MissBeat by +$1.87

One Year Ago EPS$5.09

MX:TXG Q2 2026 Revenue Results

Actual Revenue$2.74B

Expected Revenue$2.66B

Beat/MissBeat by +$79.22M

YoY Revenue Growth-12.65%

Earnings Announcement Details

QuarterQ2 2026

Date08/06/2026

TimeAfter Close

Conference CallThursday, August 6, 2026

MX:TXG Upcoming Earnings

10x Genomics's next earnings date is estimated for November 4, 2026, based on past reporting schedules.

Q2 2026 Earnings Call Audio

MX:TXG Q2 2026 Earnings Call

0:00 / 0:00

Q2 2026 Earnings Slide Deck

No slide deck is available for this earnings event.

Q2 2026 Earnings Call Summary

Q2 2026

Earnings Call Date:Aug 06, 2026|

% Change Since:

Earnings Call Sentiment|Positive

The call presented a constructive mix of operational positives — notably Atera's outsized early demand, solid consumables growth (+7% total; spatial +16%), gross margin expansion to 74%, and a raised full‑year revenue guide — while flagging near‑term cadence challenges driven by instrument revenue declines (‑47%) and manufacturing/shipment constraints for Atera that produce an expected Q3 sequential dip. The business shows healthy underlying consumable momentum and strategic positioning (M&A, multi‑omics, AI tailwinds), but short‑term instrument timing and APAC comparatives introduce visibility headwinds.

Company Guidance

Management raised 2026 revenue guidance to $610–$630 million (implying 2%–5% growth vs. 2025 ex‑nonrecurring settlements) after reporting Q2 revenue of $151.0M ($149.4M ex the $1.6M Takara settlement), a 3% YoY increase ex‑settlements; total consumables were up 7% (single‑cell consumables +3% with double‑digit reaction volume growth; spatial consumables +16%), while total instrument revenue fell 47% (Chromium -46%, spatial -48%). By region, Americas +6%, EMEA +15%, APAC -19% (prior year included ~ $4M China pull‑forward); gross margin rose to 74% (from 72%; 74% vs 67% ex‑settlements LY) helped by ~$2.6M tariff refunds; operating expenses were $132.1M vs $95M (Q2 included patent settlement gains of $3.4M in 2026 and $40.7M in 2025), cash and marketable securities totaled $552M (up $105M YoY, $12M sequentially). The company reiterated a shipment plan of ~40 Atera instruments in 2026 (weighted to Q4) — booked orders already exceed 40 but production limits keep shipments at ~40 — expects a modest Q3 sequential dip of a few million due to spatial transition dynamics and a significant Q4 step‑up largely driven by Atera (management cites Atera instrument mass utilization potential of roughly $1.5M–$3M annually, about 2× Xenium, implying substantially higher consumable pull‑through).

Quarterly Revenue and Guidance Raise

Reported Q2 revenue of $151.0M (or $149.4M excluding $1.6M non‑recurring settlement), representing 3% YoY growth on an adjusted basis. Raised full‑year 2026 revenue guidance to $610M–$630M, implying ~2%–5% YoY growth excluding non‑recurring settlement items.

Strong Consumables Performance

Total consumables revenue grew 7% YoY. Single‑cell consumables rose 3% YoY backed by double‑digit growth in reaction volumes (driven by Flex Apex), and spatial consumables increased 16% YoY with sequential growth in both Xenium and Visium (Xenium primary driver).

Atera Customer Demand and Early Orders

Commercial launch of Atera generated extraordinary customer enthusiasm and a very large number of orders in a short time; booked orders as of Q2 already greatly exceeded the previously communicated 40‑unit target for 2026, signaling strong commercial traction for the new spatial whole‑transcriptome, single‑cell sensitivity platform.

Gross Margin Expansion and Strong Liquidity

Gross margin increased to 74% from 72% YoY (and from 67% YoY when excluding non‑recurring settlement revenue). Cash, cash equivalents and marketable securities ended the quarter at $552M, up $105M YoY and $12M sequentially.

Strategic M&A to Expand Multi‑omics

Acquisition of Proteintech Genomics to enhance proteomics and multi‑omics capabilities, supporting Atera’s roadmap to add protein multi‑omics and expand platform applications.

Product and Technology Momentum

Ongoing product progress: Flex Apex driving larger perturbation/scale studies, new GEM‑X Multiome improving joint epigenetics and gene expression measurements, and launch of Catalyst Research Services to provide Atera access and sample processing—all reinforcing platform adoption and AI‑driven research demand.

MX:TXG Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change
Nov 04, 2026	2026 (Q3)	-4.76 / -	-3.995	―
Aug 06, 2026	2026 (Q2)	-4.41 / -2.54	5.085	-150.00% (-7.63)
May 07, 2026	2026 (Q1)	-4.99 / -1.82	-5.085	64.29% (+3.27)
Feb 12, 2026	2025 (Q4)	-3.69 / -2.36	-7.265	67.50% (+4.90)
Nov 06, 2025	2025 (Q3)	-5.23 / -4.00	-5.448	26.67% (+1.45)
Aug 07, 2025	2025 (Q2)	-6.72 / 5.09	-5.812	187.50% (+10.90)
May 08, 2025	2025 (Q1)	-8.48 / -5.09	-9.081	44.00% (+4.00)
Feb 12, 2025	2024 (Q4)	-5.43 / -7.26	-7.446	2.44% (+0.18)
Oct 29, 2024	2024 (Q3)	-5.98 / -5.45	-14.347	62.03% (+8.90)
Aug 08, 2024	2024 (Q2)	-8.70 / -5.81	-9.626	39.62% (+3.81)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed